GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Profitability Rank

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Profitability Rank : 6 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals Profitability Rank?

Catalyst Pharmaceuticals has the Profitability Rank of 6.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Catalyst Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 was 37.71%. As of today, Catalyst Pharmaceuticals's Piotroski F-Score is 7.


Competitive Comparison of Catalyst Pharmaceuticals's Profitability Rank

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Profitability Rank falls into.



Catalyst Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Catalyst Pharmaceuticals has the Profitability Rank of 6.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Catalyst Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=41.692 / 110.568
=37.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Catalyst Pharmaceuticals has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Catalyst Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Executives
Molly Harper director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande officer: Chief Accounting Officer 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito officer: Chief Medical Officer 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller officer: VP Development & Management 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson director C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany director, 10 percent owner, officer: President and Chief Executive C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del officer: Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd officer: Chief Compliance/Legal Officer 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe director 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram officer: Chief Product Devel. Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan officer: Chief Commercial Officer C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship officer: V.P. of Regulatory Operations 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134